Lexington, Ky.- Luitpold Pharmaceuticals, Inc., the maker of Adequan® (polysulfated glycosaminoglycan), has generously donated 100 boxes of Adequan® i.m. for use in horses selected for the short lists for the U.S. teams competing at the FEI World Equestrian Games (WEG) Tryon 2018. The donation will assist the horses in performing to the best of their abilities as they work with their human counterparts toward representing the U.S. at the WEG. Luitpold has been a proud sponsor of U.S. Equestrian Teams since 2005

“Adequan® i.m. is one of the most recognized and trusted brand names supporting equine joint health in the equestrian sporting industry,” said US Equestrian Director of Sport Will Connell. “Their support of the U.S. team is a vital part in our mission to help ensure our horses are fit, healthy, happy, and ready to compete at the FEI World Equestrian Games Tryon 2018. We place great value on the close relationship we have with Luitpold and are indebted to them for their support of the teams and also the many competitions and programs they support through their extensive sponsorship activities.”

Drs. Tim Ober, Cricket Russillo, Duncan Peters, and Susan Johns jointly said, “As the U.S. Team Veterinarians for jumping, dressage, para-equestrian dressage, and eventing, we would like to thank Luitpold for their support and dedication to the health, welfare, and competitive excellence of the U.S. team horses. As we prepare for the FEI World Equestrian Games Tryon 2018, we are all focused on ensuring our extraordinary equine athletes receive the best support possible so they can continue to demonstrate their athletic abilities at the very top of their sport. Having Adequan® i.m. available to prescribe, when a degenerative joint disease (DJD) diagnosis indicates that it may be helpful, is a benefit to us as team veterinarians as we work to support these horses staying at the top of their game.”   

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. If your equine athlete or companion horse is experiencing DJD, consult with your veterinarian and discuss whether Adequan i.m. is appropriate for your horse.

“We value our partnership with US Equestrian and supporting the teams competing at the 2018 World Equestrian Games,” stated Allyn Mann, Director of Strategic Partnerships at Luitpold Animal Health. “Our mission is to provide best of class treatments to maintain the health and well-being of the horse. We are doing that by offering our flagship product, Adequan® i.m. for use by the veterinarians to treat horses in need with an FDA approved therapy.”

Adequan® i.m. is a well-known name in the treatment of equine non-infectious degenerative joint disease (DJD). Treatment with Adequan® i.m. diminishes the destructive processes of DJD, reverses the processes that result in loss of cartilage components, and improves overall joint function and associated lameness of the carpal and hock joints. Adequan® i.m. is the only FDA-approved equine intramuscular polysulfated glycosaminoglycan.

 

IMPORTANT SAFETY INFORMATION

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.